Table 5.

Local and systemic side effects of Slovak healthcare workers who received BNT162b2 and stratified by age group, February–March 2021 (n = 522).

Variable	Outcome	18–30 Years Old (n = 179)	31–54 Years Old (n = 291)	≥55 Years Old (n = 52)	Total (n = 522)	Sig.
Local SE	Injection Site Pain	161 (89.9%)	245 (84.2%)	39 (75%)	445 (85.2%)	0.021
	Injection Site Swelling	26 (14.5%)	26 (8.9%)	1 (1.9%)	53 (10.2%)	0.018
	Injection Site Redness	21 (11.7%)	22 (7.6%)	1 (1.9%)	44 (8.4%)	0.058
	Intensity (0–3)	1.16 ± 0.69	1.01 ± 0.61	0.79 ± 0.50	1.04 ± 0.64	0.001
	Total (n)	161 (89.9%)	248 (85.2%)	39 (75%)	448 (85.8%)	0.022
Systemic SE	Fatigue	120 (67%)	149 (51.2%)	14 (26.9%)	283 (54.2%)	< 0.001
	Headache	74 (41.3%)	95 (32.6%)	10 (19.2%)	179 (34.3%)	0.009
	Fever	36 (20.1%)	41 (14.1%)	3 (5.8%)	80 (15.3%)	0.028
	Chills	57 (31.8%)	74 (25.4%)	7 (13.5%)	138 (26.4%)	0.025
	Muscle Pain	56 (31.3%)	84 (28.9%)	8 (15.4%)	148 (28.4%)	0.078
	Joint Pain	32 (17.9%)	53 (18.2%)	7 (13.5%)	92 (17.6%)	0.705
	Nausea	12 (6.7%)	34 (11.7%)	3 (5.8%)	49 (9.4%)	0.156
	Malaise	51 (28.5%)	52 (17.9%)	4 (7.7%)	107 (20.5%)	0.001
	Lymphadenopathy	13 (7.3%)	26 (8.9%)	0 (0%)	39 (7.5%)	0.048
	Intensity (0–9)	2.52 ± 2.10	2.09 ± 2.08	1.08 ± 1.66	2.14 ± 2.08	<0.001
	Total	142 (79.3%)	205 (70.4%)	21 (40.4%)	368 (70.5%)	<0.001
SE Duration	One Day	94 (56.3%)	151 (56.1%)	24 (58.5%)	269 (56.4%)	0.710
	Three Days	62 (37.1%)	86 (32%)	14 (34.1%)	162 (34%)	0.408
	Five Days	3 (1.8%)	16 (5.9%)	2 (4.9%)	21 (4.4%)	0.110
	One Week	4 (2.4%)	5 (1.9%)	1 (2.4%)	10 (2.1%)	0.897
	>One Week	4 (2.4%)	9 (3.3%)	0 (0%)	13 (2.7%)	0.544
	>One Month	0 (0%)	2 (0.7%)	0 (0%)	2 (0.4%)	0.617
General SE	Intensity (0–12)	3.68 ± 2.37	3.08 ± 2.29	1.87 ± 1.88	3.16 ± 2.33	<0.001
	Total	168 (93.9%)	269 (92.4%)	41 (78.8%)	478 (91.6%)	0.006
Severe SE	Total	0 (0%)	2 (0.7%)	0 (0%)	2 (0.4%)	0.617

Chi-squared test (χ²), Fisher’s exact test, and Kruskal–Wallis test (H) were used with a significance level (Sig.) of < 0.05.